Eliem Therapeutics Inc
NASDAQ:ELYM

Watchlist Manager
Eliem Therapeutics Inc Logo
Eliem Therapeutics Inc
NASDAQ:ELYM
Watchlist
Price: 3.09 USD -1.9% Market Closed
Market Cap: 207.7m USD
Have any thoughts about
Eliem Therapeutics Inc?
Write Note

Eliem Therapeutics Inc
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Eliem Therapeutics Inc
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
Eliem Therapeutics Inc
NASDAQ:ELYM
Common Shares Outstanding
$27.7m
CAGR 3-Years
3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Common Shares Outstanding
$1.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Common Shares Outstanding
$1.2B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Common Shares Outstanding
$537.5m
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Common Shares Outstanding
$257.7m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Common Shares Outstanding
$110.1m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
No Stocks Found

Eliem Therapeutics Inc
Glance View

Market Cap
206.4m USD
Industry
Biotechnology

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Redmond, Washington and currently employs 19 full-time employees. The company went IPO on 2021-08-10. The firm focuses on developing novel therapies for neuronal excitability disorders that addresses unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the perishable and central nervous system. The firm offers two lead clinical-stage candidates: ETX-810 and ETX-155. ETX-810 is a palmitoylethanolamide (PEA) prodrug developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (LSRP). ETX-810 is being evaluated in two Phase II a clinical trial. ETX-155 is a neurosteroid gamma-aminobutyric acid type A (GABAA) receptor positive allosteric modulator (PAM) developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures (FOS). The firm provides two programs in addition to its clinical candidates, namely Kv7.2/3 program and anxiolytic.

ELYM Intrinsic Value
1.59 USD
Overvaluation 49%
Intrinsic Value
Price

See Also

What is Eliem Therapeutics Inc's Common Shares Outstanding?
Common Shares Outstanding
27.7m USD

Based on the financial report for Dec 31, 2023, Eliem Therapeutics Inc's Common Shares Outstanding amounts to 27.7m USD.

What is Eliem Therapeutics Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 3Y
3%

Over the last year, the Common Shares Outstanding growth was 4%. The average annual Common Shares Outstanding growth rates for Eliem Therapeutics Inc have been 3% over the past three years .

Back to Top